PMID: 8448750Mar 1, 1993Paper

Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B

Cancer
R MirB Peterson

Abstract

This article reviews the salient pathologic and clinical features of 171 patients with Stage III-IV disease who were 60 years of age or older who were treated on four Hodgkin disease (HD) protocols from 1969 to 1988. Pretherapy sections were reviewed centrally for correlation of the histologic classification with anatomic sites of involvement and survival. The diagnosis of HD was confirmed in 114 (66.7%) patients. Non-Hodgkin lymphomas (NHL) and a miscellaneous non-HD group accounted for 52 (30.4%) and 5 (2.9%) of the cases. The overall median survival times of patients with Stage III-IV HD and NHL who were 60 years of age or older in the four protocols were not significantly different (1.5 versus 1.3 years, respectively; P = 0.28). There also was no significant correlation between the survival of these patients with HD and either the Rye classification, 19 specific histologic parameters, or the British National Lymphoma Investigation grading system for HDNS. In the last protocol, the 5-year survival rate of patients with HD who were 60 years of age or older was lower than that of patients 40-59 years of age or that of those younger than 40 years of age (31% versus 63% versus 79%, respectively, P < 0.0001). Patients with HD ent...Continue Reading

References

Mar 18, 1978·British Medical Journal·S B SutcliffeJ S Malpas
Jan 11, 1975·Journal of Surgical Oncology·C SayJ S Spratt
Apr 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M RoachR T Hoppe
Aug 1, 1990·British Journal of Cancer·P SelbyM Gore
Dec 1, 1988·European Journal of Cancer & Clinical Oncology·A P TerblancheL Matzner
Aug 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G C HenkelmannL M Fuller
Jan 1, 1987·Journal of the National Cancer Institute·J W DavisB K Armstrong
Sep 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K J PropertA J Gottlieb
Mar 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A KantE S Jaffe
Dec 1, 1985·Cancer·B J KennedyC Mettlin
Jan 1, 1974·Oncology·J J LokichW C Moloney
Jul 1, 1973·Cancer·A S PatchefskyW S Hoch
Jun 1, 1972·Cancer·L M AxtellG R Newell
Jul 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M R CooperJ F Holland
Jan 1, 1984·Annals of Internal Medicine·M M Austin-SeymourH S Kaplan
May 1, 1982·Cancer·T V ColbyR A Warnke
Sep 1, 1981·Clinical Radiology·M H BennettG V Hudson

❮ Previous
Next ❯

Citations

May 10, 2011·Current Hematologic Malignancy Reports·Teresa V HalbsguthVolker Diehl
Jun 23, 2000·Critical Reviews in Oncology/hematology·H EghbaliP Richaud
Jun 21, 2013·Hematological Oncology·Deepa JagadeeshAndrew M Evens
Mar 25, 2000·Journal of the American Geriatrics Society·B J KennedyH R Menck
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas EngertUNKNOWN German Hodgkin's Study Group
Mar 20, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew M Evens, Fangxin Hong
Feb 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Colin D WeekesUNKNOWN Nebraska Lymphoma Study Group
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian SteidlRandy D Gascoyne
Sep 5, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew M EvensPaul A Hamlin
Nov 9, 2018·British Journal of Haematology·Boris Böll, Helen Görgen
Dec 7, 2019·Hematology·Andrew M EvensKevin A David
Apr 25, 2020·Current Treatment Options in Oncology·Jordan CarterAndrew M Evens

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
A LevisIntergruppo Italiano Linfomi (IIL)
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Colin D WeekesNebraska Lymphoma Study Group
British Journal of Haematology
Gail L StarkNorthern Region Lymphoma Group
© 2021 Meta ULC. All rights reserved